Roche shells out $200M for rights to Vaccibody's neoantigen cancer vaccine
Roche’s Genentech arm is putting down $200 million in upfronts and near-term payments — and potentially $515M more down the road — for global rights to Norwegian biotech Vaccibody’s neoantigen cancer vaccine candidate.
The companies are joining forces to develop Vaccibody’s personalized vaccine candidate VB10.NEO in the US and Europe. According to the licensing agreement, Vaccibody will see the candidate through Phase Ib development, after which the big guns at Genentech will take over clinical development, manufacturing and commercialization.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,400+ biopharma pros reading Endpoints daily — and it's free.